A meaningful DCF fair value isn't available for Krystal Biotech, Inc. (KRYS) — its free-cash-flow and net-debt profile makes a standard discounted-cash-flow model unreliable (common for loss-makers and high-net-debt or recently-public companies), and no analyst DCF is published. Explore your own assumptions with the editable model below.
The FMP figure is a third-party point estimate. Its cash-flow forecast, discount rate, terminal growth, and valuation date are not included in the stored response, so TGMCharts presents it only as a reference—not as an intrinsic-value conclusion or price target.
Current Price
$326.17
Market-Implied Growth
N/A
Base-Case Model Value
N/A
Edit the assumptions to see how they change the estimated fair value. Opens seeded with TGM's data-driven base case for KRYS (growth from its own 5-year record, discount from its beta), so the sandbox starts where the scenarios above leave off. Illustrative model — not investment advice.
Base inputs: FCF $9.3M · 0.03B shares · net cash $496.3M
Estimated Fair Value
$24.03
-92.6% vs $326.17
How the estimated fair value shifts with the discount rate (WACC) and terminal growth, holding your 5.0%/yr FCF growth and 10-year horizon fixed. Green = above today's $326.17; red = below. Your current case is outlined.
| WACC ↓ / Terminal → | 1.50% | 2.00% | 2.50% | 3.00% | 3.50% |
|---|---|---|---|---|---|
| 5.5% | $26.17 | $27.33 | $28.88 | $31.05 | $34.30 |
| 6.5% | $24.28 | $24.98 | $25.85 | $26.97 | $28.46 |
| 7.5% | $23.02 | $23.48 | $24.03 | $24.70 | $25.54 |
| 8.5% | $22.12 | $22.44 | $22.82 | $23.26 | $23.79 |
| 9.5% | $21.44 | $21.68 | $21.95 | $22.26 | $22.62 |
